Alexion Pharmaceuticals - March is #WilsonDiseaseAwarenessMonth. #Wilsondisease is a rare and progressive genetic disorder in which the body's pathway for removing excess copper is broken or disabled. People living with this #raredisease
Wilson disease | Nature Reviews Disease Primers
Alexion to acquire Wilson Therapeutics in $855m deal
Alexion adds to pipeline rebuild with $855m Wilson buy - PMLiVE
Functional characterization of novel or yet uncharacterized ATP7B missense variants detected in patients with clinical Wilson's disease - Stalke - 2023 - Clinical Genetics - Wiley Online Library
Alexion on X: "Patients living with Wilson disease can develop a wide range of symptoms, including liver disease and/or psychiatric or neurological symptoms. For further advice and support: https://t.co/nrPzQ4A3F4 #WilsonDiseaseAwarenessMonth https://t ...
AstraZeneca celebrates copper-bottomed deal after Alexion purchase
Data backs AZ's Wilson disease drug, but with a question mark | pharmaphorum
THINK WILSON
Alexion inks $855M takeover of Wilson Therapeutics | Fierce Biotech
Alexion Pharmaceuticals - Decades of low awareness and limited scientific research of Wilson disease, a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised, have
Wilson disease. - Abstract - Europe PMC
Wilson Disease - Practical Neurology
Alexion Acquires Swedish Treatment for Wilson's Disease
Wilson Therapeutics - Wikipedia
Wilson disease | Nature Reviews Disease Primers
Clinical Advances in Wilson Disease: A Journey From Suspicion to Diagnosis to Management
Alexion Reports Positive Results from Phase 3 Trial of ALXN1840 in Wilson Disease - Global Genes
Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
Alexion's drug meets primary goal in Phase III Wilson disease trial
Wilson's Disease Treatment Market To Rise Exponentially in Future
ALXN1840 FoCus Phase III trial in Wilson disease hits goal
Evaluating diagnosis and management gaps in wilson disease: results from a qualitative patient survey
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology
Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline | BioSpace
ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues-CliniExpert
Alexion to Acquire Wilson Therapeutics for $855 Million - Equities News
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
TETA4 Noninferior to Penicillamine for Stable Wilson's Disease | MedPage Today
Alexion Acquires Swedish Treatment for Wilson's Disease
